David A. Siegel Rain Therapeutics Inc. Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.84 - $1.22 $50,232 - $72,956	-59,800 Reduced 27.57%	157,100 $188,000
Q3 2023 Nov 14, 2023	BUY	$0.82 - $1.42 $78,228 - $135,468	95,400 Added 78.52%	216,900 $186,000
Q2 2023 Aug 14, 2023	BUY	$1.09 - $9.93 $101,043 - $920,511	92,700 Added 321.88%	121,500 $145,000
Q1 2023 May 15, 2023	BUY	$7.77 - $12.47 $223,776 - $359,136	28,800 New	28,800 $251,000
Q2 2022 Aug 15, 2022	SELL	$2.21 - $5.56 $29,835 - $75,060	-13,500 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.07 - $13.68 $68,445 - $184,680	13,500 New	13,500 $68,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.